A003220 Stock Overview
A pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
Daewon Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,580.00 |
| 52 Week High | ₩20,700.00 |
| 52 Week Low | ₩13,910.00 |
| Beta | 0.42 |
| 11 Month Change | -0.14% |
| 3 Month Change | -4.58% |
| 1 Year Change | -12.54% |
| 33 Year Change | -3.73% |
| 5 Year Change | -4.74% |
| Change since IPO | 220.27% |
Recent News & Updates
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Aug 13
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors
Jul 17Recent updates
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Aug 13Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors
Jul 17There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings
Mar 21Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Mar 26Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?
Mar 07Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?
Feb 18Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 31
Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?
Jan 13Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend
Dec 24Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly
Dec 10Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?
Nov 22Shareholder Returns
| A003220 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 4.1% | -1.5% | 2.4% |
| 1Y | -12.5% | 4.6% | -4.0% |
Return vs Industry: A003220 underperformed the KR Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: A003220 underperformed the KR Market which returned -3.8% over the past year.
Price Volatility
| A003220 volatility | |
|---|---|
| A003220 Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A003220 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A003220's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 1,260 | Seung-Ryel Baek | www.daewonpharm.com |
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease.
Daewon Pharmaceutical Co., Ltd. Fundamentals Summary
| A003220 fundamental statistics | |
|---|---|
| Market cap | ₩312.50b |
| Earnings (TTM) | ₩14.69b |
| Revenue (TTM) | ₩566.09b |
21.3x
P/E Ratio0.6x
P/S RatioIs A003220 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A003220 income statement (TTM) | |
|---|---|
| Revenue | ₩566.09b |
| Cost of Revenue | ₩292.94b |
| Gross Profit | ₩273.15b |
| Other Expenses | ₩258.47b |
| Earnings | ₩14.69b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 685.29 |
| Gross Margin | 48.25% |
| Net Profit Margin | 2.59% |
| Debt/Equity Ratio | 67.3% |
How did A003220 perform over the long term?
See historical performance and comparison